Vimarsana
Biggest News Aggregation in the World

Fred Lublin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fred Lublin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fred Lublin Today - Breaking & Trending Today

KPIX CBS Evening News With Scott Pelley December 22, 2016 - Vimarsana News

KPIX CBS Evening News With Scott Pelley December 22, 2016

Pelley this is our western edition. As a manhunt spreads across europe tonight, president elect trump says the berlin Christmas Market attack proves that he is right about cracking down on muslim immigration to america. German police say the suspect is an immigrant from tunisia with a connection to isis. And Julianna Goldman begins our coverage. Whats going on is terrible. Reporter president elect donald trump emerged from his Maralago Club to briefly address this weeks terrorist attack in berlin, his first Public Comments since a truck plowed into a Christmas Market killing 12. Reporter asked...

Top minds in multiple sclerosis to speak at CMSC 38th Annual Meeting - Vimarsana News

Top minds in multiple sclerosis to speak at CMSC 38th Annual Meeting

The leading research and educational conference for multiple sclerosis healthcare professionals in North America, the Consortium of Multiple Sclerosis Centers (CMSC) 38th Annual Meeting, returns to Nashville, Tennessee, May 29-June 1, 2024 at the Music City Center.

Immunic, Inc. (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript - Vimarsana News

Immunic, Inc. (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript

Jessica Breu: Good morning and welcome to Immunic's Fourth Quarter and Year End 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.

EQS-News: Immunic, Inc.: Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential - Vimarsana News

EQS-News: Immunic, Inc.: Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential - Vimarsana News

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...